Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.4
Journals
Medicina
Special Issues
Treatment Updates and Outcomes for Solid Organ and Blood Cancers
share announcement

Treatment Updates and Outcomes for Solid Organ and Blood Cancers

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Hematology and Immunology".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 2087

Special Issue Editors

Dr. Abdullah Esmail

E-Mail Website
Guest Editor
1. Section of Gastrointestinal Oncology—Houston Methodist Neal Cancer Center and Institute of Academic Medicine, 6445 Fannin, OPC-24, Houston, TX 77030, USA
2. Houston Methodist Research Institute, Houston, TX 77030, USA
Interests: transplant oncology; liver cancer; cholangiocarcinoma; targeted therapy; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Dr. Qiang Wang

E-Mail Website
Guest Editor
1. Instructor of Cancer Biology in Medicine, Houston Methodist, Academic and Research Institute, Houston, TX 77030, USA
2. Dr. Mary and Ron Neal Cancer Center, Houston Methodist, Houston, TX 77030, USA
Interests: cancer biology; solid cancers; hem-oncology; immunotherapy

Special Issue Information

Dear Colleagues,

In the face of rising cancer rates worldwide, effective therapeutic interventions are crucial for improving patient outcomes, particularly in solid organ and blood cancers. As numerous contentious, yet widely employed, methods and treatment approaches, as well as the clinical investigation of solid organ and blood malignancies, are apparently rising, the quest for systematic evaluation/review and standardization of these approaches is urgently crucial for optimizing survival rates and patient treatment. This Special Issue aims to present and evaluate diverse treatment approaches to optimize survival rates and refine treatment protocols.

We emphasize the need for standardized methodologies and targeted inquiry into areas ripe for advancement. Collaborative efforts among multidisciplinary trial teams validate emerging trends and expand treatment modalities.

Recent advancements in hepatobiliary malignancies highlight the impact of collaborative teams and innovative therapies on improving survival rates. The emergence of novel options in immuno-oncology offers opportunities for tailored treatment regimens.

This Special Issue presents a cohesive narrative on patient outcomes and updates on cutting-edge treatments and diagnostics, aiming to bridge the gap between research and clinical practice for more effective cancer care.

In this Special Issue, original research articles and reviews are welcome. Research areas may include, but are not limited to, the following: solid organ cancers, blood malignancies, chemotherapy, cancer immunotherapy, oncology, systemic treatment, diagnosis, or targeted therapy.

Dr. Abdullah Esmail
Dr. Qiang Wang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • solid organ cancers
  • blood malignancies
  • chemotherapy
  • immunotherapy cancers
  • oncology
  • systemic treatment
  • diagnosis and targeted therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

7 pages, 1162 KiB  
Case Report
Cardiac Paraganglioma in a Young Patient Presents with Angina-like Symptoms: A Case Report and Literature Review
by Batool Wael Alnahar, Bushray Almiqlash, Hala Hassanain, Ebtesam Al-Najjar, Abdullah Esmail, Asma Zainab and Iqbal Ratnani
Medicina 2024, 60(9), 1495; https://doi.org/10.3390/medicina60091495 - 13 Sep 2024
Viewed by 625
Abstract
Paragangliomas are rare extra-adrenal neuroendocrine tumors originating from chromaffin tissue that present a diagnostic and therapeutic challenge due to their diverse clinical manifestations and low incidence. While these tumors often manifest as catecholamine-secreting functional tumors, their clinical presentation can vary, leading to delayed [...] Read more.
Paragangliomas are rare extra-adrenal neuroendocrine tumors originating from chromaffin tissue that present a diagnostic and therapeutic challenge due to their diverse clinical manifestations and low incidence. While these tumors often manifest as catecholamine-secreting functional tumors, their clinical presentation can vary, leading to delayed diagnosis and challenging management. This study presents the case of a 22-year-old patient with cardiac paraganglioma who initially presented with angina-like symptoms, highlighting the importance of considering this rare condition in young individuals with nonspecific complaints. Diagnostic imaging, including transthoracic echocardiography, CT angiography, and MRI, played a crucial role in identifying the tumor’s location and vascularization. Surgical excision, including pulmonary artery graft and CABG, was the primary management approach, which was accompanied by intraoperative complications that later led to CCU admission, followed by postoperative complications, ultimately leading to the patient’s death. This case highlights the significance of early recognition and management of complications following a surgical approach to treat paragangliomas. Full article
(This article belongs to the Special Issue Treatment Updates and Outcomes for Solid Organ and Blood Cancers)
►▼ Show Figures

Figure 1

7 pages, 1935 KiB  
Case Report
The Uncharted Territories of Esophageal Cancer with Cardiac and Skeletal Muscle Metastasis: A Case Report and Literature Review
by Hala Hassanain, Omar Hassanain and Maen Abdelrahim
Medicina 2024, 60(7), 1146; https://doi.org/10.3390/medicina60071146 - 16 Jul 2024
Viewed by 1097
Abstract
Background: Esophageal cancer (EC) comprises 1% of all diagnosed cancers in the USA. It is more common in other parts of the world. If there is distant metastasis, the relative survival rate is 6%. There are no standardized screening methods for EC. Case [...] Read more.
Background: Esophageal cancer (EC) comprises 1% of all diagnosed cancers in the USA. It is more common in other parts of the world. If there is distant metastasis, the relative survival rate is 6%. There are no standardized screening methods for EC. Case Presentation: We reported a four-year case of esophageal cancer, a P53-positive mutation with atypical distant metastasis to the cardiac and skeletal muscles. The patient was managed with multimodal therapy, including immunotherapy, which could have been a factor in prolonged survival. Conclusions: Distant metastases are typically seen postmortem, and with prolonged survival, we are able to find such unique metastases antemortem. Despite a history of negative scans, the patient’s ctDNA (circulating tumor DNA) remained positive, which was a better predictor of recurrence in this case. Future research is required to establish cost-effective screening methods and standardized treatments. Full article
(This article belongs to the Special Issue Treatment Updates and Outcomes for Solid Organ and Blood Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop